If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 1.00 (0.96%)
Spread: 6.00 (5.882%)
Open: 104.00
High: 105.00
Low: 104.00
Prev. Close: 104.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

9 Dec 2008 07:00

RNS Number : 7601J
Intercede Group PLC
09 December 2008
 



9 DECEMBER 2008

INTERCEDE GROUP plc

('Intercede', 'the Company' or 'the Group')

Interim Results for the 6 Months Ended 30 September 2008

Intercede (AIM: IGP.L) is a leading developer of identity and Credential Management software, called MyID, which manages the secure registration, issuance and life cycle of digital identities for a wide range of uses. 

SUMMARY

28% increase in sales to £1,981,000 (2007: £1,546,000)

Excluding impact of one-off advance payment in September 2007, underlying sales increased by 90% over a 12 month cycle

Gross margin 99% (2007: 99%)

Operating profit of £268,000 (2007: £90,000)

Profit before tax of £222,000 (2007: £45,000)

Cash inflow before financing of £606,000 (2007: £244,000)

Cash balances of £1,839,000 at 30 September 2008 (30 September 2007: £1,575,000)

Continued good progress in US Federal Government market: 200,000 licenses now sold, demonstrating successful ongoing penetration of the large and growing PIV market

Significant sub-contract with Lockheed Martin valued in excess of $1m

Participation in two National Identity contracts with an aggregate current year revenue potential of $1.8m

Richard Parris, Chairman & Chief Executive of Intercede, said today:

"Our performance during this period is the best ever. As a result we are firmly on track to achieve full year profitability. Significant interest in our MyID security solution by both the public and private sectors has resulted in strong sales growth throughout the world. Importantly, we are not seeing our business activity adversely affected by economic conditions. We are very excited about the size and scope of contracts we are working on and we are looking forward to making further progress on all fronts."

  ENQUIRIES

Intercede Group plc

Tel.+44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Pelham Public Relations

Archie Berens

Tel.+44 (0)20 7743 6679

Robert Koh

KBC Peel Hunt

Richard Kauffer

Tel.+44 (0)20 7418 8900

About Intercede

  Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and lifecycle management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments include 10 US Federal Agencies, the US Transportation Worker Identity Credential (TWIC) and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

For more details visit www.intercede.com

  INTERCEDE GROUP plc

Interim Results for the Six Months Ended 30 September 2008

Chairman's Statement

Business Review

I am pleased to be able to report that excellent commercial and technical progress has been made during the first half of the year. Revenues have increased by 28% to £1,981,000 (2007: £1,546,000), resulting in a profit before tax of £222,000 compared to £45,000 in the same period last year. 

As we reported in our trading update at the beginning of October 2008, the equivalent period last year included a one-off upfront licence order of £0.5 million from Thales, whereas this period's sales performance only includes 'business as usual' revenue items. Taking this into account, underlying sales have increased by 90% within a 12 month cycle.

As a result of this improved performance and careful cash management, cash balances at 30 September 2008 totaled £1,839,000, an increase of £686,000 during the year to date. At the time of reporting in December 2008, Intercede's cash balances have further increased to £2,289,000demonstrating continued positive cash generation.

This represents a turning point in the evolution of Intercede's business and is indicative of the strong commercial progress we continue to make.

Significant advances during the year to date include:

Contracts have been won to supply the Intercede MyID Identity and Credential Management System in support of two national identity card programmes. One of these projects is in the Middle East region. These contracts have an aggregate current year revenue potential of US$1.8m.

A sub-contract for MyID products and services has been signed with Lockheed Martin worth an initial US$1.0m.

More than 400,000 US Transport Workers Identity Cards (TWIC) have now been issued using MyID.

A Solutions Partnership Contract has been signed with Operational Research ConsultantsORC has supplied MyID product and services to the United Space Alliance, Federal Trade Commission, Federal Housing Finance Administration and the Federal Election Commission. 

Additionally, ORC has launched a MyID powered service for credentialing civilian contractors accessing US military bases.

 

6. As a matter of public record, it is noted that the US Federal Aviation Authority (FAA) has purchased Intercede’s MyID Identity and Credential Management System from VeriSign and has installed it at the core of its HSPD-12/PIV implementation.
7. Intercede has also delivered MyID licenses to a further US Federal agency via an existing partner. This is a non-PIV application with a large growth potential.
8. The successful deployment of a MyID system at a leading German manufacturing company.
9. The sale and installation of MyID in support of a large UK Government service provider.

 

In addition to the above projects, Intercede continues to work, via our US partners, with multiple US Federal Agencies on their PIV programmes and has to date sold more than 200,000 licenses under the US Government's HSPD-12 initiative. This constitutes successful ongoing penetration of the large and growing PIV market

Intercede has entered this year with a significant number of its technical resources contracted to extend the functionality of MyID to support national identity and government-to-citizen projects around the world. These activities have contributed to the high utilisation of our staff, significantly strengthen and expand our product capabilities and once again demonstrate the scalability of MyID and the world-class expertise of our team.

In the private sector we are benefiting from steadily increasing sales of MyID in support of business-to-employee smart card based identity systems, a trend that we expect to continue in both the US and Europe.

Financial Results

Sales during the period totaled £1,981,000 which, at a gross margin of 99%, resulted in an operating profit of £268,000. This compares with sales in the corresponding period last year of £1,546,000 at a gross margin of 99% and an operating profit of £90,000.

Continued tight control over costs and cash management resulted in a £606,000 cash inflow before financing which compares with a £244,000 inflow during the comparative period. This inflow resulted in cash balances totaling £1,839,000 as at 30 September 2008.

Intellectual Property

On 1 October 2008, ActivIdentity filed a patent infringement action against Intercede in the Northern District of California. ActivIdentity alleges that Intercede infringes U.S. Patent No. 6,575,360. Intercede has retained the services of Allen & Overy as legal counsel and the firm of Fenwick & West LLP as litigation counsel in the US. Intercede believes that it has meritorious defences to this action and intends to defend itself vigorously.

Outlook

The first half of the year has been profitable and cash generative. Furthermore, orders received to date in the second half of this year are strong and guarantee that we will exceed the full year financial performance of the previous period in terms of revenue, profit and cash generationAs in previous years, the full year outcome will be dependent upon the timing of receipt of orders and our subsequent ability to deliver and recognise revenues in accordance with the Group's accounting policy. Nevertheless, the level and pace of customer and partner activity is at an all time high and I remain confident that this year represents a step change in Intercede's commercial development.

Richard Parris

Chairman & Chief Executive

9 December 2008

  Intercede Group plc

Consolidated Income Statement (Unaudited) 

6 months ended

6 months ended

Year ended

30 September

30 September

31 March

2008

2007

2008

£'000

£'000

£'000

Continuing operations

Revenue

1,981

1,546

2,805

Cost of sales

(25)

(21)

(30)

 

 

 

Gross profit

1,956

1,525

2,775

Administrative expenses

(1,688)

(1,435)

(2,877)

 

 

 

Operating profit/(loss)

268

90

(102)

Investment revenue

28

23

61

Finance costs

(74)

(68)

(136)

 

 

 

Profit/(loss) before tax

222

45

(177)

Tax

61

90

90

 

 

 

Profit/(loss) for the period

283

135

(87)

Earnings per share (pence)

- basic 

0.8p

0.4p

(0.2)p

- diluted 

0.6p

0.3p

(0.2)p

  Intercede Group plc

Consolidated Balance Sheet (Unaudited) 

As at

As at

As at

30 September

30 September

31 March

2008

2007

2008

£'000

£'000

£'000

Non-current assets

Property, plant and equipment

57

37

52

Current assets

Trade and other receivables

866

223

419

Cash and cash equivalents

1,839

1,575

1,153

 

 

 

2,705

1,798

1,572

Total assets

2,762

1,835

1,624

Equity

Share capital

4,302

4,292

4,292

Share premium account

2,834

2,764

2,764

Other reserves

1,508

1,508

1,508

Equity reserve

109

109

109

Retained earnings

(9,568)

(9,629)

(9,851)

 

 

 

Total equity

(815)

(956)

(1,178)

Current liabilities

Trade and other payables

493

470

350

Deferred revenue

1,177

556

619

Convertible loan notes

1,907

-

-

 

 

 

3,577

1,026

969

Non-current liabilities

Convertible loan notes

-

1,765

1,833

 

 

 

Total equity and liabilities

2,762

1,835

1,624

  Intercede Group plc

Consolidated Statement of Changes in Equity (Unaudited)

Share 

Share 

Other 

Equity 

Retained 

Capital

Premium

reserves

reserve

earnings

Total

£'000

£'000

£'000

£'000

£'000

£'000

At 31 March 2008

4,292

2,764

1,508

109

(9,851)

(1,178)

Issue of shares, net of costs

10

70

-

-

-

80

Retained profit for the period

-

-

-

-

283

283

 

 

 

 

 

 

At 30 September 2008

4,302

2,834

1,508

109

(9,568)

(815)

At 31 March 2007

4,271

2,107

1,508

109

(9,764)

(1,769)

Issue of shares, net of costs

21

657

-

-

-

678

Retained profit for the period

-

-

-

-

135

135

 

 

 

 

 

 

At 30 September 2007

4,292

2,764

1,508

109

(9,629)

(956)

At 31 March 2007

4,271

2,107

1,508

109

(9,764)

(1,769)

Issue of shares, net of costs

21

657

-

-

-

678

Retained loss for the period

-

-

-

-

(87)

(87)

 

 

 

 

 

 

At 31 March 2008

4,292

2,764

1,508

109

(9,851)

(1,178)

 

Intercede Group plc

Consolidated Cash Flow Statement (Unaudited)

6 months ended

6 months ended

Year ended

30 September

30 September

31 March

2008

2007

2008

£'000

£'000

£'000

Cash flows from operating activities

Operating profit/(loss)

268

90

(102)

Depreciation

12

8

18

(Increase)/decrease in trade and other receivables

(441)

12

(184)

Increase/(decrease) in trade and other payables

701

29

(29)

Taxation received

61

90

90

Net cash from operating activities

601

229

(207)

Investing activities

Interest received

22

22

61

Purchases of property, plant and equipment

(17)

(7)

(32)

 

 

 

Net cash from investing activities

5

15

29

Financing activities

Proceeds on issue of shares

80

678

678

 

 

 

Net increase in cash and cash equivalents

686

922

500

Non-cash movement

(74)

(68)

(136)

Net debt at beginning of period

(680)

(1,044)

(1,044)

 

 

 

Net debt at end of period

(68)

(190)

(680)

  

Intercede Group plc

Notes to the Accounts

 

1. Preparation of the interim financial statements

These interim financial statements have been prepared under IFRS on the basis of the accounting policies set out in the Group's Annual Report for the year ended 31 March 2008. They were approved by the Board of Directors on December 2008.

The Group is not required to apply IAS 34 Interim Financial Reporting at this time.

These interim financial statements do not constitute statutory accounts as defined in Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 March 2008 have been delivered to the Registrar of Companies. The Auditors' Report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985, but it did contain an emphasis of matter paragraph.

The Interim Report will be mailed to shareholders prior to the end of December 2008 and copies will be available on the website (www.intercede.com) and at the registered office: Intercede Group plc, Lutterworth Hall, St Mary's Road, Lutterworth, Leicestershire, LE17 4PS.

 

2. Segmental Reporting

 

All of the Group's revenue, operating losses and net assets originate from operations in the United Kingdom. The Directors consider that the activities of the Group constitute a single class of business.

The split of revenue by geographical destination can be analysed as follows:

6 months ended

6 months ended

Year ended

30 September

30 September

31 March

2008

2007

2008

£'000

£'000

£'000

United Kingdom

882

857

1,378

Rest of Europe

380

114

298

USA

704

572

1,085

Rest of World

15

3

44

 

 

 

1,981

1,546

2,805

 

3. Earnings per share

 

The calculation of earnings per ordinary share are based on the profit/(loss) for the period and the weighted average number of ordinary shares in issue during each period i.e. September 2008: 36,871,850; September 2007: 35,569,896 and March 2008: 35,831,101. The diluted earnings per share is based on a weighted average of 48,735,009 (September 2007: 48,211,164) which reflects the potential conversion of all existing convertible loan stock, warrants and share options. Basic and diluted earnings per share are the same for the year ended 31 March 2008 as potential dilution cannot be applied to a loss making period.

4. Dividend

 

The Directors do not recommend the payment of a dividend.

 

5. Analysis and reconciliation of net debt

6 months ended

6 months ended

Year ended

30 September

30 September

31 March

2008

2007

2008

£'000

£'000

£'000

Cash and cash equivalents 

1,839

1,575

1,153

Convertible loan notes

(1,907)

(1,765)

(1,833)

Net debt

(68)

(190)

(680)

The convertible loan notes mature on 31 May 2009 at which point each of the loan note holders will elect whether to exercise their conversion rights (at exercise prices of 15p and 20p per ordinary share for the original £450,000 and £982,000 loans respectively), agree to a further extension of the loans or request the repayment of their portion of the loans plus accrued interest to that point. The total potential repayment including interest is £2,005,000.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ILFITFLLTIIT
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.